CompletedPhase 3

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

Belgium, Finland83 participantsStarted 2000-01

Plain-language summary

Study of efficacy \& safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Serum Sodium 115 to \<130mEq/L * Plasma Osmolarity \<290 mOsmol/kg H2O Exclusion Criteria: * Significant renal insufficiency * Serum sodium increase of ≥8 mEq/L over the baseline day ( Hours 0 to 12)

What they're measuring

Change in serum sodium from Baseline Safety of each dosing regimen

Timeframe: Beginning through end of treatment

Trial details

NCT IDNCT00492037

SponsorCumberland Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Hyponatremia trials